<unk>  (LAAO), also referred to as<unk><unk><unk>  closure (LAAC) is a treatment strategy to reduce the risk of<unk><unk><unk>  blood clots from entering the bloodstream and causing a stroke in patients with non-valvular<unk>  fibrillation (AF). In non-valvular AF, over 90% of stroke-causing clots that come from the heart are formed in the<unk><unk><unk> . The most common treatment for AF stroke risk is treatment with blood-thinning medications, also called oral anticoagulants, which reduce the chance for blood clots to form. These medications (which include warfarin, and other newer approved blood thinners) are very effective in lowering the risk of stroke in AF patients. Most patients can safely take these medications for years (and even decades) without serious side effects. However, some patients find that blood thinning medications can be difficult to tolerate or are risky. Because they prevent blood clots by thinning the blood, blood thinners can increase the risk of bleeding problems. In select patients, physicians determine that an alternative to blood thinners is needed to reduce AF stroke risk. Approximately 45% of patients who are eligible for warfarin are not being treated, due to tolerance or adherence issues. This applies particularly to the elderly, although studies have indicated that they can also benefit from anticoagulants.<unk><unk><unk>  closure is an implant-based alternative to blood thinners. Like blood thinning medications, an LAAC implant does not cure AF. A stroke can be due to factors not related to a clot traveling to the brain from the<unk>  atrium. Other causes of stroke can include high blood pressure and narrowing of the blood vessels to the brain. An LAAC implant will not prevent these other causes of stroke.
Left atrial appendage occlusion
Left anterior fascicular block
Left posterior fascicular block
Primary ventricular fibrillation
Alcohol septal ablation
Spontaneous coronary artery dissection
Aortic valvuloplasty
Left ventricular thrombus